SynCAR Medicine

Synthekine is a clinical-stage biotechnology company focused on developing next-generation cytokine therapeutics to treat cancer and autoimmune diseases. The company utilizes its proprietary SynCAR (Synthetic Cytokine and Receptor) platform to engineer cytokine-based therapies with improved selectivity, potency, and safety profiles. Their lead program, SYNCAR 001, is a CD19-targeted CAR-T cell therapy that incorporates a modified IL-2 receptor to enhance T-cell expansion and persistence. Synthekine's pipeline also includes orthogonal cytokine-receptor pairs and biased cytokine agonists designed to overcome the limitations of traditional cytokine treatments. By precisely tuning immune responses, the company aims to provide transformational outcomes for patients with high unmet medical needs.